Intravenous ibandronate in men with osteoporosis: an open pilot study over 2 years

Détails

ID Serval
serval:BIB_23B72C29CB27
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Intravenous ibandronate in men with osteoporosis: an open pilot study over 2 years
Périodique
Journal of Endocrinological Investigation
Auteur(s)
Lamy  O., Sandini  L., Pache  I., Fatio  S., Burnand  J., Burckhardt  P.
ISSN
0391-4097 (Print)
Statut éditorial
Publié
Date de publication
08/2003
Volume
26
Numéro
8
Pages
728-32
Notes
Clinical Trial
Journal Article --- Old month value: Aug
Résumé
In the treatment of osteoporosis, the tolerance of oral bisphosphonates is often low. The high potency of ibandronate allows iv bolus injections that can be repeated every 2 to 3 months. However, the best dose and time interval of the treatment with iv ibandronate is still debated. Efficacy of 2-mg ibandronate injected every 3 months was tested in men with osteoporosis over 2 yr, in a prospective, open study. Fourteen men with primary osteoporosis, mean age 57 +/- 12 yr (range: 40-73), received 2-mg ibandronate iv every 3 months over 2 yr. All got 1 g/day calcium and 880 UI/day vitamin D for 2 yr. Bone mineral density (BMD) increased after 2 yr by 6.7 +/- 1.5% (mean change +/- SEM) at lumbar spine (p<0.001), by 3.2 +/- 08% at trochanter (p<0.001) and by 1.4 +/- 1.1% at femoral neck (ns). Serum beta-crosslaps and osteocalcin decreased significantly by 30-45 and 30%, respectively, during the 2 yr of treatment. Serum calcium increased from the lower to the middle tertile of the normal range during the 2 yr of the study. The observed decrease of bone remodelling and the increase of BMD are of the same magnitude as those described with oral bisphosphonates. The increase of plasma calcium confirms the positive effect of the supplementation with calcium and vitamin D. These results suggest that 3 months are a good interval between two doses of iv ibandronate, when 2 mg are given.
Mots-clé
Adult Aged Aged, 80 and over Biological Markers Bone Density/drug effects Bone and Bones/metabolism Diphosphonates/administration & dosage/adverse effects/*therapeutic use Follow-Up Studies Fractures, Bone/epidemiology Humans Injections, Intravenous Male Middle Aged Osteoporosis/*drug therapy/pathology Pilot Projects Spine/anatomy & histology/pathology
Pubmed
Web of science
Création de la notice
25/01/2008 14:55
Dernière modification de la notice
20/08/2019 14:01
Données d'usage